Open Call for Patient Input – Joint Assessment on a medicinal product for DLBCL.
Patient group input requested for a new Joint Assessment on a medicinal product for DLBCL.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ and carers/care-givers’ views and experiences by engaging with a wide range of patients. They can describe advantages and disadvantages of medicinal treatments based on patients’ experiences and what patients value from a new treatment.
EUnetHTA recently started a new Joint Assessment on a medicinal product for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant.
For this specific assessment on a medicinal product for DLBCL, an ‘open call for patient group submission’ is used. We are seeking European and national patient organisations to provide an organisational perspective on the questions in English. In all parts of this form the term ‘patient’ refers to anyone living with, or who has lived with, the condition for which the new medicine is indicated. The information provided will inform the scope of the assessment, e.g. on patient relevant outcomes or possible neglected outcomes, as well as on the burden of disease.
The questions in this call are taken from the HTAi questionnaire template. For more information on the development of the HTAi questionnaire template please see their website.
EUnetHTA strives to be transparent in the information used and at the same time we recognise that completing this form requires substantial resources. Therefore, we commit ourselves to making all patient submissions publically available at our webpage at the timing of publication of the project plan for this assessment. In due course, this can be found here. Of course, we will anonymise the data from individual patients prior to publication. Furthermore, our Joint Assessment report will document how the information from patients was considered in developing the scope of our EUnetHTA Joint Assessment.
If you are interested in submitting information, please go to the questionnaire below and submit your input before March 31st, 16:00PM CET.
Please see below for further guidance on how to complete this questionnaire. If you have any questions when completing this form, please contact EUnetHTA Pharmaceutical Joint Assessment Co-Lead Partner, Zorginstituut Nederland at WP4_Pharmaceuticals@zinl.nl
Many thanks for your valuable input!
Patient group input – relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for patients who are not candidates for hematopoietic stem cell transplant.
 We are working on translating the questionnaire to national languages so that individual patients can also submit information. Unfortunately, this will not be possible for this specific assessment on a medicinal product for DLBCL.
To collect your information, we use a GDPR-compliant access tool called Crowdsignal that allows owners of quizzes, polls, and other surveys to safely field respondent information.
This tool allows respondents to look up and request the deletion of their responses and related personal information. Delete requests are accompanied by your email address and the country from which you are making the request.
A cookie is used to keep you logged into this page. It holds a randomly generated string that is also recorded on our servers. This then expires within an hour unless you navigate further around this page.
If, pending your review, you would like to request that your information be deleted, Crowdsignal will pass on your request to us. Your email address will be sent as part of this request response. You should reach out to us for any further inquiries about your personal information or responses.
Your IP address indicates you are making this request from inside the EU.
Review your submission HERE.